A Phase 3 interventional study of Triptorelin embonate 22.5 mg in Prostate Cancer, sponsored by Debiopharm International SA. Completed at 10 sites in South Africa. Open to male participants. Per ClinicalTrials.gov, last updated 2015-09-15.
Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 14th largest by enrollment, is one of 3 that started in 2012, is one of 12 in phase 3, and was the 12th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+ · Men only
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Sites in Spain
Ages 18+
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 6
First in 2002; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 120 across the 28 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Debiopharm International SA, one of the names counted as Debiopharm. Under that name alone:
Debiopharm International SA is the lead sponsor of 51 studies on the registry; 6 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Debiopharm has 3 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing triptorelin in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851547Ottawa Hospital Research InstituteDose Escalation For INtraprostatic LEsions | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of triptorelin embonate 22.5 mg 6-month formulation administered by the subcutaneous (under the skin) route in:
Summary Inclusion Criteria:
Summary Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
Drug: Triptorelin embonate 22.5 mg
Also known as: Pamorelin
Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L)
Time frame: within 337 days
Percentage of Participants Showing ≤ 1.0 IU/L Increase in Serum Luteinising Hormone (LH) From 0 Hour to 2 Hours Post-injection on Day 1 and Day 169
Time frame: on Days 1 and 169
Percentage Change From Baseline in Prostate Specific Antigen (PSA) Through Day 337
Time frame: Baseline through Day 337
Number of Participants Who Presented a Real "Acute-on-chronic" (AOC) Phenomenon (Testosterone Levels ≥ 1.735 Nmol/L 48 Hours After the Second Injection While Previously Castrated)
Time frame: Day 171
Testosterone Pharmacodynamic (PD) Metrics for First Injection: Area Under the Concentration vs Time Curve (AUC)
Time frame: Days 1-169
Testosterone PD Metrics for First Injection: Maximum Concentration (Cmax)
Time frame: Days 1-169
Testosterone PD Metrics for First Injection: Time to Peak Serum/Plasma Concentration (Tmax)
Time frame: Days 1-169
Testosterone PD Metrics for First Injection: Time to Castration (Tcast)
Time frame: Days 1-169
Triptorelin PK Metrics for Both Injections: Area Under the Concentration vs Time Curve (AUC)
Time frame: Days 1-169 and Days 169-337
Triptorelin PK Metrics for Both Injections: Cmax
Time frame: Days 1-169 and Days 169-337
Triptorelin PK Metrics for Both Injections: Concentration 0 Hour
Time frame: Days 1-169 and Days 169-337
Participants took part in the study at 10 hospital settings in South Africa, from 03 July 2012 to 30 August 2013.
| Milestone | Triptorelin Embonate 22.5 mg |
|---|---|
| Started | 120 |
| Received triptorelin at day 1 | 120 |
| Received triptorelin at day 169 | 115 |
| Completed | 113 |
| Not completed | 7 |
| Withdrew: Death | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Percentage of Participants | Triptorelin Embonate 22.5 mg |
|---|---|
| Achieving (by Day 29) | 98.33 (94.11 to 99.80) |
| Maintaining (Day 57 to Day 337) | 82.61 (74.43 to 89.04) |
| percentage of participants | Triptorelin Embonate 22.5 mg |
|---|---|
| on Day 1 (n=118) | 0.85 (0.02 to 4.63) |
| on Day 169 (n=115) | 87.83 (80.42 to 93.18) |
| percentage of change in PSA levels | Triptorelin Embonate 22.5 mg |
|---|---|
| at Day 85 (n=119) | -83.20 ± 38.10 |
| at Day 169 (n=117) | -83.48 ± 38.29 |
| at Day 253 (n=114) | -85.43 ± 33.94 |
| at Day 337 (n=113) | -82.89 ± 40.74 |
| participants | Triptorelin Embonate 22.5 mg |
|---|---|
| Number of Participants Who Presented a Real "Acute-on-chronic" (AOC) Phenomenon (Testosterone Levels ≥ 1.735 Nmol/L 48 Hours After the Second Injection While Previously Castrated) | 1 |
| day*nmol/L | PK/PD Subset |
|---|---|
| Testosterone Pharmacodynamic (PD) Metrics for First Injection: Area Under the Concentration vs Time Curve (AUC) | 224.13 (175.82 to 285.72) |
| nmol/L | PK/PD Subset |
|---|---|
| Testosterone PD Metrics for First Injection: Maximum Concentration (Cmax) | 16.52 (12.74 to 21.41) |
| hours | PK/PD Subset |
|---|---|
| Testosterone PD Metrics for First Injection: Time to Peak Serum/Plasma Concentration (Tmax) | 48 ± 40.02 |
| days | PK/PD Subset |
|---|---|
| Testosterone PD Metrics for First Injection: Time to Castration (Tcast) | 18.01 (16.45 to 19.72) |
| days * ng/mL | PK/PD Subset |
|---|---|
| AUC(1-169) | 61.30 (53.50 to 70.25) |
| AUC(169-337) | 66.44 (58.99 to 74.82) |
| ng/mL | PK/PD Subset of 15 Participants |
|---|---|
| Days 1-169 | 16.77 (13.33 to 21.09) |
| Days 169-337 | 18.09 (14.11 to 23.20) |
| ng/mL | PK/PD Subset |
|---|---|
| Days 1-169 | 0.04 (0.02 to 0.09) |
| Days 169-337 | 0.07 (0.04 to 0.11) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triptorelin Embonate 22.5 mg | — | 17/120 (14.2%) | 117/120 (97.5%) |
| Event | Triptorelin Embonate 22.5 mg |
|---|---|
| Atrial fibrillationCardiac disorders | 3/120 |
| HyperglycaemiaEndocrine disorders | 2/120 |
| Myocardial ischaemiaCardiac disorders | 2/120 |
| Acute myocardial infarctionCardiac disorders | 1/120 |
| AnaemiaBlood and lymphatic system disorders | 1/120 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 1/120 |
| Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/120 |
| CystitisInfections and infestations | 1/120 |
| DeathGeneral disorders | 1/120 |
| Deep vein thrombosisBlood and lymphatic system disorders | 1/120 |
| Event | Triptorelin Embonate 22.5 mg |
|---|---|
| Hot flushVascular disorders | 86/120 |
| HypertensionVascular disorders | 14/120 |
| Urinary tract infectionInfections and infestations | 13/120 |
| ConstipationGastrointestinal disorders | 11/120 |
| LethargyGeneral disorders | 11/120 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/120 |
| Erectile dysfunctionReproductive system and breast disorders | 10/120 |
| Back painMusculoskeletal and connective tissue disorders | 9/120 |
| Upper respiratory tract infectionInfections and infestations | 8/120 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/120 |
Safety Analysis Set, defined as all enrolled subjects who received at least one dose of study treatment.
| Age, Continuous(years) | Triptorelin Embonate 22.5 mg |
|---|---|
| Mean | 72.23 ± 7.32 |
| Sex: Female, Male(Participants) | Triptorelin Embonate 22.5 mg |
|---|---|
| Female | 0 |
| Male | 120 |
| Region of Enrollment(participants) | Triptorelin Embonate 22.5 mg |
|---|---|
| South Africa | 120 |
The record gives a start of Jul 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin